Jamie Platt, PHD

---

Jamie Platt is an experienced and recognized leader in clinical genomics and molecular diagnostics. After completing a PhD in Molecular Biology and fellowship as a Post-Doctoral Scholar at UC Berkeley, Jamie focused her academic and research interests toward innovation and application in clinical diagnostics. Jamie spent nearly 15 years at Quest Diagnostics, overseeing both Operational and R&D functions, beginning with Infectious Disease and ultimately initiating and overseeing Quest’s Advanced Sequencing (Genomics) program spanning Genetics, Oncology, Immunology, Infectious Disease, and Neurology. Jamie and her team developed and validated the first commercially available NGS-based diagnostic in 2006, helping to transform NGS technology from an influential research tool to a viable and powerful clinical platform. Jamie ultimately oversaw the entire Advanced Sequencing (NGS) portfolio for all of Quest Diagnostics and continued to grow the genomics business both organically and through acquisition (e.g., Athena Diagnostics and Celera). Leading the translation of NGS technology from research into clinical diagnostics, also allowed her to develop an extensive professional network collaborating on projects with high-profile key opinion leaders like George Church, Eric Topol, and Francis Collins (Director of The NIH). Jamie’s early experience in clinical NGS also led her to contribute to professional guidelines in NGS, such as CLSI MM09, NYS NGS Guidelines for Somatic Variant Detection, NIST Genomes In-A-Bottle, and the FNIH QCM Project for ctDNA (circulating tumor DNA). After leaving Quest Diagnostics, Jamie focused on helping laboratories, pharmaceutical companies, and platform (instrument) providers bridge gaps in their knowledge of genomics applications and the market landscape. Jamie has helped more than 25 laboratories achieve CLIA licensure, in addition to gaining CAP accreditation (7 laboratories), ISO 15189 & ISO 14385 certification (5 entities), NYS CLEP (2 laboratories) CE Mark (3 products), FDA Breakthrough Device Designation (2 products), and Local Coverage Determination (LCD) for CMS via Palmetto MolDx. Jamie has supported several FDA PMA and 510K submissions by NGS platform providers (Illumina and ThermoFisher) through clinical and orthogonal studies. Jamie also serves as an NGS specialized auditor for CAP (The College of American Pathologists)and is a member of the C21 (Coalition for 21st Century Medicine) Regulatory Working Group. Jamie is frequently invited as a key-note speaker, podium presenter, and workshop instructor at research and professional conferences. Her recent experience in liquid biopsy and personalized medicine is a natural extension and evolution of a career committed to enabling significant clinical diagnostic insights through genomics.